The deadline to submit your #LungCancer essay is March 31! #OncologyFellows, don’t miss this chance to join an exclusive group of 30 fellows in Chicago this May for research, networking, and career-changing opportunities. Submit today: https://lnkd.in/gK8v79D5
关于我们
OncLive is the official website for the Intellisphere, LLC Oncology Specialty Group, which publishes OncologyLive, Urologists in Cancer Care, Oncology Nursing News, and Oncology Fellows. The mission of OncLive is to arm oncology professionals with the resources and information they need to provide the best patient care. We cover every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. OncLive allows the Oncology Specialty Group to add features and tools not possible with print, such as social media feeds, breaking news, and live coverage from major oncology meetings.
- 网站
-
https://onclive.com
OncLive的外部链接
- 所属行业
- 图书期刊出版业
- 规模
- 51-200 人
- 总部
- Cranbury，NJ
- 类型
- 私人持股
地点
-
主要
获取路线
2 Clarke Dr
US，NJ，Cranbury，08512
OncLive员工
-
Chandler Park, M.D., F.A.C.P.
Award Winning Oncologist| 3x NEJM Published Author| ASCO Faculty|Advisory Dean/Clinical Professor UofL Medical School|Kentucky Leader ASCO ASH NCCN…
-
Julie Ruff, RDN
National Account Manager | OncLive Medical?| Medical Affairs | Sales
-
Morgan Burum
Director of Sales
-
Jack Nirenberg
National Accounts Manager at OncLive | Working With Commercial & Clinical Oncology Partners on NPP and P2P Marketing Solutions
动态
-
Watch Catherine Lee, MD of?Fred Hutch?present a post-hoc analysis of the AGAVE-201 trial, demonstrating that axatilimab achieves consistent overall response rates in patients with chronic graft-versus-host disease regardless of prior lines of therapy. https://lnkd.in/gued_P9P
-
Hear Laura Huppert MD of?University of California, San Francisco?present data from the DESTINY-Breast12 study, showcasing the effects of trastuzumab deruxtecan on health-related quality of life and neurological function in HER2+ metastatic breast cancer. https://lnkd.in/gu5hZEFk
-
Grzegorz S. Nowakowski, MD, of the Mayo Clinic discusses the FDA approval of brentuximab vedotin plus lenalidomide and rituximab for relapsed/refractory LBCL. #oncology #LBCL https://lnkd.in/ekiJ_J9c
-
Tune in to watch Margaret T. Kasner, MD and Christian Fidler, MD of?Jefferson Health?discuss how secondary AML presents unique challenges in diagnosis, classification, and treatment due to its complex pathogenesis and evolving classification criteria. https://lnkd.in/gU3MM3Nw
-
BREAKING: FDA Approves Pembrolizumab Plus Trastuzumab/Chemo for PD-L1+, HER2+ Gastric/GEJ Adenocarcinoma #Oncology https://lnkd.in/dmA_Ke36
-
-
Watch the on-demand presentation, “Leading the Way: Approaches in Biomarker Testing for HRD, a Standardized Approach,” for tips on building relationships and providing educational support to your colleagues. Gain insight on building a consensus for standardized biomarker testing for homologous recombination deficiency, also referred to as HRD, in patients with advanced ovarian cancer from S. Michelle Shiller, DO, AP/CP, MGP. https://hubs.li/Q03cs3bv0
-
-
The FDA has granted orphan drug designation to HLX22 for the treatment of patients with gastric cancer based on positive data from the HLX22-GC-201 study. #oncology https://lnkd.in/e8tYftQY
-
Tune in to hear Maurie Markman, MD of City of Hope explore the profound role of hope in cancer care. Drawing from recent public discussions, Dr. Markman examines how a cancer diagnosis impacts patients, families, and society—highlighting the importance of survivorship, resilience, and emotional well-being throughout the treatment journey. Watch only on our YouTube channel: https://lnkd.in/gq_PqMA9.?
-
-
Leading gynecologic oncologists Angeles Alvarez Secord, MD, Dana Chase, MD, Bhavana Pothuri, MD, Premal Thaker, MD and Thomas C (MD) Krivak, MD—delve into frontline maintenance strategies for advanced ovarian cancer. ?? Watch the full discussion here: https://lnkd.in/gYVVNktS